Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


13.06.24 / Frankfurt WKN: A2PZ7S / Name: Visiomed / Stock / Healthcare Equipment & Supplies / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Visiomed Group Stock

Visiomed Group gained 0.120% compared to yesterday.
The community is currently still undecided about Visiomed Group with 1 Buy predictions and 0 Sell predictions.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Visiomed Group stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Visiomed Group in the next few years

G***** c******* t* c**********
S********** s********
W********* I********* f** t** n*** y****
C******** o* t** e**********
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Visiomed Group vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Visiomed Group 0.120% -2.465% -11.690% -67.977% -35.581% -51.882% -
Crossject S.A. 1.260% 0.227% -2.000% -47.422% -61.145% -30.414% -7.158%
Implanet S.A. -4.080% -3.689% -8.738% -28.463% 76.360% -89.318% -97.330%
Thermogenesis Holdings Inc. 28.460% -33.333% -45.517% -72.281% -44.561% -99.702% -99.730%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-02

Considering the information at hand, it seems that Visiomed, a player in the Healthcare Equipment and Supplies industry, is navigating through some financial challenges, while also seizing on growth opportunities. These insights come from an examination of their financial statements and key ratios over the years.

Delving deeper into their financials, one might notice a pattern of increasing total assets from 2020 to 2022. This positive trajectory could signal an expanding business scope, perhaps due to strategic investments or acquisitions. Likewise, the gross profit, while still negative in 2020, improved over the next two years, hinting at stronger operational efficiency.

However, worries exist. Visiomed posted losses from 2020 to 2022, as indicated by negative net income figures. The current picture is one of ongoing financial strain, marked by a worsened net debt situation in 2022 and negative working capital in 2020. Plus, the negative free cash flow across the board raises liquidity concerns.